RepliCel Life Sciences, Inc. operates as a regenerative medicine company. The company focuses on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. Its products includes RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin, and pattern baldness. The company was founded on April 24, 1967 and is headquartered in Vancouver, Canada.
Company profile
Ticker
REPCF
Exchange
Website
CEO
Robert Lee Buckler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEWCASTLE RESOURCES LTD., PAN AMERICAN GOLD CORP, TRI LATERAL VENTURE CORP
SEC CIK
REPCF stock data
Latest filings (excl ownership)
6-K
RepliCel announces a Letter of Intent for Asset Purchase Agreement
20 Mar 24
6-K
Condensed Consolidated Interim Financial Statements
30 Nov 23
6-K
Condensed Consolidated Interim Financial Statements
24 Oct 23
6-K
Current report (foreign)
19 Oct 23
6-K
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
4 Oct 23
6-K
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
13 Sep 23
6-K
Current report (foreign)
7 Sep 23
6-K
Notice of Annual General and Special Meeting of Shareholders
30 Aug 23
6-K
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
29 Aug 23
6-K
Annual General and Special Meeting
17 Aug 23
Latest ownership filings
SC 13D/A
Schutte Andrew
20 Apr 23
SC 13D/A
Schutte Andrew
26 Jan 23
SC 13D/A
MACKAY JAMIE MYLES
5 Jan 23
SC 13D
MACKAY JAMIE MYLES
29 Sep 22
SC 13D/A
Schutte Andrew
2 Jun 22
SC 13D/A
MAINPOINTE PHARMACEUTICALS, LLC
21 Dec 21
SC 13D
MAINPOINTE PHARMACEUTICALS, LLC
4 Jun 21
SC 13D/A
Schutte Andrew
17 Sep 20
SC 13D
Replicel Life Sciences Inc.
12 Sep 18
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2022
6.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 3.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Mainpointe Pharmaceuticals | 3.99 mm | $0.00 |